tirzepatide latest news Zepbound copycats remain online despite FDA ban Lilly launches lower-price weight loss

A Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023) reported that participants receiving higher doses of retatrutide (up to 12 mg) achieved mean body weight reductions of approximately 1724% over 48 weeks

Primary endpoint was defined as adverse events associated with treatment

At DeMayo Law Offices, we can help you add your case to the ongoing litigation against this company

Patients with severe liver impairment should be assessed by a specialist before considering these medications

Between June and July 2025, when the formulary change was implemented, switching from AOM tirzepatide increased, while patients with an active supply of AOM semaglutide showed stable or even slightly reduced switching during the same period, consistent with its designation as the preferred option

Immunity boost Why it matters: Zinc, selenium, and high-dose vitamin C help white blood cells act faster